临床分期 |
|
| 11.409 | 0.001 |
I~II期 | 28/1 | 96.6 |
|
|
III~IV期 | 12/8 | 60 |
|
|
B症状 |
|
| 16.163 | 0.000 |
有 | 7/6 | 53.8 |
|
|
无 | 33/3 | 91.7 |
|
|
IPI评分 |
|
| 4.846 | 0.028 |
0~2 | 33/5 | 86.8 |
|
|
3~5 | 7/4 | 63.6 |
|
|
HGB |
|
| 0.003 | 0.954 |
<100 | 14/3 | 82.4 |
|
|
≥100 | 26/6 | 81.3 |
|
|
ALB |
|
| 8.752 | 0.003 |
<35 | 8/6 | 57.1 |
|
|
≥35 | 32/3 | 91.4 |
|
|
LDH |
|
| 4.697 | 0.03 |
升高 | 6/4 | 60 |
|
|
正常 | 34/5 | 87.2 |
|
|
β2微球蛋白a |
|
| 3.381 | 0.066 |
升高 | 9/5 | 64.3 |
|
|
正常 | 15/2 | 88.2 |
|
|
病理分型 |
|
| 7.426 | 0.006 |
B细胞源性 | 38/7 | 84.4 |
|
|
T细胞源性 | 2/2 | 50 |
|
|
治疗方式 |
|
| 2.676 | 0.102 |
单纯手术 | 4/3 | 57.1 |
|
|
手术 + 化疗 | 22/4 | 84.6 |
|
|
单纯化疗 | 14/2 | 87.5 |
|
|